Please login to the form below

Not currently logged in
Email:
Password:

AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance

He joins the biopharma from Tang Capital Management

AVEO Oncology has appointed Dr Nikhil Mehta as senior vice president or regulatory and quality assurance, a role that will see him oversee all aspects of regulatory, quality and technical operations for the company’s portfolio.

Dr Mehta brings over 25 years’ experience in biotechnology and pharmaceutical industries to AVEO and most recently, Dr Mehta served as executive vice president and chief regulatory strategies at Tang Capital Management, where he was involved in establishing two biopharmaceutical companies.

Prior to Tang Capital, he served as global head of regulatory affairs at Baxalta and before that, he was vice president, global regulatory affairs, oncology, haematology, immunology and diagnostics at Merck & Co.

He has also held roles for Shire, Bristol-Myers Squibb and Hoffman-La Roche.

Michael Baily, president and chief executive officer, AVEO, said: “Dr Mehta brings to AVEO a depth of experience in regulatory affairs and oncology that we believe will be invaluable as we plan and advance our US registration strategy for tivozanib as a potential treatment for renal cell carcinoma.”

“I anticipate Dr Mehta’s integration into the AVEO team will be seamless and rapidly productive and we look forward to working with him.”

11th December 2017

From: Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics